PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
25746333-9	2015	We also found that lower viral replication after LiCl treatment was associated with the reduced mRNA levels of pro-inflammatory IL-8, IL-6, IL-1 beta, tumor necrosis factor alpha and decreased NF-kappaB nuclear translocation.	Lithium Chloride	49-53	interleukin 6	Homo sapiens	134-138	
23988651-9	2013	In contrast, in aged DCs, LiCl reduced the secretion of TNF-alpha and IL-6 in LPS stimulated DCs but did not increase IL-10.	Lithium Chloride	26-30	interleukin 6	Homo sapiens	70-74	
20672290-11	2011	The effect of LiCl on IL-6/IL-8/IL-10 secretion in iDC is mediated through inhibition of GSK-3beta.	Lithium Chloride	14-18	interleukin 6	Homo sapiens	22-26	
11267862-7	2001	LiCl, a potent inhibitor of Glycogen Synthase Kinase 3beta (GSK3beta) activity, abrogated the IL-6-induced inhibition of wild-type beta-catenin.	Lithium Chloride	0-4	interleukin 6	Homo sapiens	94-98	
29049420-8	2017	Furthermore, DAPT and LiCl decreased production of IL-1beta, TNF-alpha, IL-6, iNOS, Cox2 and MCP-1; however, IL-10 expression was increased notably in LiCl treated cells.	Lithium Chloride	22-26	interleukin 6	Homo sapiens	72-76	
26593276-5	2016	We found that lithium chloride (LiCl), a widely used GSK3 inhibitor and the mainstay treatment for bipolar disorder, reinforced the LPS adaptive response by enhancing both downregulation of pro-inflammatory genes (inducible nitric oxide synthase, interleukin 1beta, interleukin 6, tumor necrosis factor alpha), and upregulation of genes typically associated to anti-inflammatory functions (interleukin 10 and MRC1).	Lithium Chloride	14-30	interleukin 6	Homo sapiens	266-308	
26593276-5	2016	We found that lithium chloride (LiCl), a widely used GSK3 inhibitor and the mainstay treatment for bipolar disorder, reinforced the LPS adaptive response by enhancing both downregulation of pro-inflammatory genes (inducible nitric oxide synthase, interleukin 1beta, interleukin 6, tumor necrosis factor alpha), and upregulation of genes typically associated to anti-inflammatory functions (interleukin 10 and MRC1).	Lithium Chloride	32-36	interleukin 6	Homo sapiens	266-308	
9210006-0	1997	In vitro effects of lithium chloride on TNF alpha and IL-6 production by monocytes from breast cancer patients.	Lithium Chloride	20-36	interleukin 6	Homo sapiens	54-58	
9210006-2	1997	In this study we have evaluated the in vitro effect of LiCl on TNF alpha and interleukin-6 (IL-6) release by monocytes from patients affected by non-metastatic (BCa/M0) and metastatic breast cancer (BCa/M1), preincubated with autologous serum (sPt).	Lithium Chloride	55-59	interleukin 6	Homo sapiens	77-90	
9210006-2	1997	In this study we have evaluated the in vitro effect of LiCl on TNF alpha and interleukin-6 (IL-6) release by monocytes from patients affected by non-metastatic (BCa/M0) and metastatic breast cancer (BCa/M1), preincubated with autologous serum (sPt).	Lithium Chloride	55-59	interleukin 6	Homo sapiens	92-96	
9210006-6	1997	Moreover, the results obtained from the same cells, preincubated in sPt and treated with LiCl, indicate that serum factors may synergize with LiCl treatment in releasing IL-6.	Lithium Chloride	89-93	interleukin 6	Homo sapiens	170-174	
9210006-6	1997	Moreover, the results obtained from the same cells, preincubated in sPt and treated with LiCl, indicate that serum factors may synergize with LiCl treatment in releasing IL-6.	Lithium Chloride	142-146	interleukin 6	Homo sapiens	170-174